3h
Zacks Investment Research on MSNSarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results